Lung cancer: trials for referral

Opened for recruitment

Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study

NCT07880353 · No phase · China

Status changed: Running, not recruiting → Completed

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

NCT07024862 · No phase · United States

New in the registry

A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer

NCT07920549 · Phase 2/3 · Canada

Opened for recruitment

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

NCT07803848 · Phase 2 · Germany

Opened for recruitment

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

NCT07843940 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France

Status changed: Recruiting → Not yet recruiting

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France

Opened for recruitment

Boosting Osimertinib Blood Brain Barrier Penetration

NCT07485452 · Phase 2 · Netherlands

Status changed: Recruiting → Not yet recruiting

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

NCT07420439 · Phase 2 · France

Status changed: Recruiting → Not yet recruiting

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786 · Phase 2 · Spain

Phase changed: Phase 1 → Phase 1/2

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

NCT07151040 · Phase 1/2 · Spain, France, United Kingdom

Opened for recruitment

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

NCT07158489 · Phase 2 · Switzerland, Ireland

Closed for recruitment

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883 · Phase 3 · China, Spain, Georgia, Greece, Hungary, India

Opened for recruitment

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706 · Phase 3 · Belgium, Canada, China, Germany, Spain, France

Phase changed: Phase 2 → Phase 2/3

High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy

NCT07213375 · Phase 2/3 · Denmark

Opened for recruitment

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583 · Phase 1/2 · Spain, France, United States

Opened for recruitment

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727 · Phase 1 · Canada, Germany, Spain, France, Italy, Japan

Phase changed: Phase 1 → Early Phase 1

Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)

NCT07007325 · Early Phase 1 · France

Opened for recruitment

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy

Opened for recruitment

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055 · Phase 2 · Australia, Spain, United Kingdom, South Korea, United States

Opened for recruitment

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813 · Phase 1 · China, Spain, Israel, Japan, Puerto Rico, Taiwan

Closed for recruitment

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369 · Phase 3 · Armenia, Brazil, Germany, Spain, Georgia, Greece

Status changed: Completed → Running, not recruiting

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil

Opened for recruitment

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907 · Phase 2 · Chile, Spain, Greece, Hungary, Israel, Italy

Closed for recruitment

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522 · Phase 2 · Australia, Belgium, Brazil, Canada, Switzerland, China

Closed for recruitment

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844 · Phase 3 · Belgium, Brazil, Canada, Germany, Spain, France

Opened for recruitment

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

Opened for recruitment

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 · Phase 1 · Australia, China, Denmark, Spain, Poland

Phase changed: Phase 1/2 → Phase 1

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 · Phase 1 · Australia, China, Denmark, Spain, Poland

Closed for recruitment

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan

Phase changed: Phase 1 → Early Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

NCT06645808 · Early Phase 1 · Netherlands

Opened for recruitment

PET-imaging of Two Vartumabs in Patients With Solid Tumors

NCT06645808 · Early Phase 1 · Netherlands

Phase changed: Phase 1 → Early Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

NCT06639191 · Early Phase 1 · Sweden

Status changed: Completed → Running, not recruiting

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768 · Phase 1/2 · Argentina, Brazil, China, Spain, France, Italy

Opened for recruitment

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808 · Phase 1 · Canada, Spain, France, Italy, United States

Opened for recruitment

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

NCT06457789 · Phase 2/3 · Netherlands

Opened for recruitment

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 · Phase 3 · Australia, Brazil, Canada, China, Germany, Spain

Status changed: Recruiting → By invitation only

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

NCT06419179 · Phase 2 · Germany

Closed for recruitment

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721 · Phase 3 · Argentina, Austria, Bulgaria, Brazil, Chile, Germany

Phase changed: Phase 1 → Phase 3

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721 · Phase 3 · Argentina, Austria, Bulgaria, Brazil, Chile, Germany

Phase changed: Phase 2/3 → Phase 2

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NCT06219317 · Phase 2 · Belgium, Spain, France, Italy, Netherlands

Closed for recruitment

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NCT06219317 · Phase 2 · Belgium, Spain, France, Italy, Netherlands

Closed for recruitment

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil

Closed for recruitment

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Chile

Closed for recruitment

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441 · Phase 2 · Australia, Chile, Germany, Spain, France, Georgia

Phase changed: Phase 2 → Phase 1/2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221 · Phase 1/2 · Austria, Australia, Czechia, Germany, Denmark, Spain

Closed for recruitment

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836 · Phase 3 · Argentina, Austria, Brazil, Canada, Switzerland, Chile

Status changed: Completed → Running, not recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782 · Phase 2 · Argentina, Australia, Chile, France, Japan, New Zealand

Closed for recruitment

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom

Closed for recruitment

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575 · Phase 2 · Brazil, Spain, France, Greece, Croatia, Hungary

Closed for recruitment

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

NCT05856695 · Phase 2 · France, Luxembourg

Opened for recruitment

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil

Phase changed: Phase 3 → Phase 4

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

NCT05874401 · Phase 4 · Austria, Belgium, Bulgaria, Germany, Spain, Greece

Closed for recruitment

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767 · Phase 2/3 · Australia, Canada, Spain, France, Georgia, Greece

Phase changed: Phase 1 → Phase 1/2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168 · Phase 1/2 · Australia, Canada, China, Germany, Spain, United Kingdom

Status changed: Completed → Running, not recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879 · Phase 1 · Australia, Spain, France, Italy, South Korea, Taiwan

Opened for recruitment

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

NCT05701176 · Phase 1/2 · Netherlands

Opened for recruitment

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249 · Phase 2 · France

Phase changed: Phase 1/2 → Phase 1

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585 · Phase 1 · Germany, Spain, France, United Kingdom, Italy, United States

Status changed: Running, not recruiting → Completed

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708 · Phase 2 · Australia, Brazil, Canada, China, Spain, France

Closed for recruitment

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591 · Phase 2 · Germany, Spain, Georgia, South Korea, Poland, Taiwan

Status changed: Completed → Running, not recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578 · Phase 2 · Spain, France, Greece, Hungary, Italy, Poland

Opened for recruitment

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280 · Phase 2 · Spain, Italy, United States

Closed for recruitment

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073 · Phase 1 · Australia, Canada, China, Spain, France, United Kingdom

Phase changed: Phase 2/3 → Phase 2

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

NCT05401786 · Phase 2 · Netherlands

Opened for recruitment

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

NCT05492682 · Phase 1 · Germany, Italy

Status changed: Completed → Running, not recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385 · Phase 2 · Belgium, Canada, Switzerland, Czechia, Germany, Spain

Status changed: Completed → Running, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843 · Phase 2 · Argentina, Austria, Belgium, Brazil, China, Germany

Opened for recruitment

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094 · Phase 2 · Spain

Phase changed: Phase 4 → Phase 3

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

NCT05298423 · Phase 3 · Argentina, Austria, Australia, Brazil, Chile, China

Opened for recruitment

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

NCT05344209 · Phase 2 · Norway

Closed for recruitment

THIO Sequenced With Cemiplimab in Advanced NSCLC

NCT05208944 · Phase 2 · Australia, Bulgaria, Georgia, Hungary, Poland, Romania

Phase changed: Phase 2 → Phase 1/2

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132 · Phase 1/2 · Spain, Georgia, Ireland, Italy, Poland, United States

Status changed: Completed → Running, not recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075 · Phase 3 · Argentina, Australia, Canada, China, Spain, Finland

Closed for recruitment

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696 · Phase 1/2 · Austria, Belgium, Canada, China, Czechia, Germany

Status changed: Completed → Running, not recruiting

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT05143970 · Phase 1 · Belgium, France

Status changed: Completed → Running, not recruiting

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

NCT05012254 · Phase 2 · Spain

Closed for recruitment

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882 · Phase 1 · Australia, Germany, Spain, France, Israel, Japan

Status changed: Completed → Running, not recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654 · Phase 1/2 · Canada, China, Spain, France, Georgia, Japan

Closed for recruitment

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282 · Phase 2 · Spain, France, Italy

Closed for recruitment

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811 · Phase 2 · Canada, China, Spain, France, Italy, Japan

Closed for recruitment

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, China

Opened for recruitment

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804 · Phase 1 · Austria, Australia, Belgium, China, Germany, Spain

Opened for recruitment

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305 · Phase 1 · Australia, Belgium, Brazil, Canada, China, Spain

Phase changed: Phase 3 → Phase 2

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173 · Phase 2 · Spain, France, Greece, Hong Kong, Ireland, South Korea

Phase changed: Phase 1/2 → Phase 2

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133 · Phase 2 · Argentina, Bulgaria, China, United States

Opened for recruitment

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449 · Phase 1/2 · Argentina, China, Czechia, United Kingdom, Japan, Mexico

Status changed: Completed → Running, not recruiting

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

NCT04547504 · Phase 3 · France

Status changed: Completed → Running, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691 · Phase 1 · Spain, Italy, Japan, Taiwan, United States

Opened for recruitment

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States

Status changed: Completed → Running, not recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599 · Phase 1/2 · Germany, Denmark, Spain, France, United Kingdom, Georgia

Status changed: Completed → Running, not recruiting

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099 · Phase 1/2 · France, South Korea, United States

Phase changed: Phase 2 → Phase 1/2

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070 · Phase 1/2 · Canada, Spain, Hungary, Israel, Italy, South Korea

Opened for recruitment

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070 · Phase 1/2 · Canada, Spain, Hungary, Israel, Italy, South Korea

Status changed: Completed → Running, not recruiting

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

NCT04223596 · Phase 2 · Spain

Closed for recruitment

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154 · Phase 3 · Argentina, Brazil, Spain, Greece, Mexico, Peru

Status changed: Completed → Running, not recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859 · Phase 1 · Canada, Spain, United States

Status changed: Completed → Running, not recruiting

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

NCT03970746 · Phase 1/2 · Belgium, Germany, France, Netherlands, Poland

Status changed: Completed → Running, not recruiting

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701 · Phase 1 · Spain, France, United Kingdom, United States

Status changed: Completed → Running, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465 · Phase 1 · Austria, Belgium, Spain, South Korea, Poland, Russia

Status changed: Completed → Running, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486 · Phase 2 · Belgium, United Kingdom, Hungary, India, Japan, South Korea

Status changed: Completed → Running, not recruiting

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297 · Phase 3 · Argentina, Belgium, Canada, China, Czechia, Germany

Status changed: Completed → Running, not recruiting

NADIM II: Neo-Adjuvant Immunotherapy

NCT03838159 · Phase 2 · Spain

Status changed: Running, not recruiting → Completed

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

NCT03446547 · Phase 2 · Finland, Norway, Sweden

Opened for recruitment

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

NCT03467360 · Phase 1 · France, Monaco

Status changed: Completed → Running, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643 · Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, China

Phase changed: Phase 2/3 → Phase 2

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617 · Phase 2 · Austria, Canada, Germany, Spain, France, Israel

Status changed: Completed → Running, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992 · Phase 2 · Austria, Belgium, Switzerland, China, Germany, Spain

Closed for recruitment

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940 · Phase 2 · Poland, United States

Phase changed: Phase 1/2 → Phase 2

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224 · Phase 2 · Australia, Canada, Spain, France, United Kingdom, Hungary

Phase changed: Phase 1/2 → Phase 1

Trial of BMS-986012 in Combination With Platinum and Etoposide

NCT02815592 · Phase 1 · Spain

Status changed: Completed → Running, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804 · Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, China

Status changed: Completed → Running, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106 · Phase 3 · Australia, Belgium, Brazil, Canada, China, Germany

Status changed: Completed → Running, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448 · Phase 3 · Canada, Germany, Spain, France, United Kingdom, Greece

Opened for recruitment

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940 · Phase 2 · Poland, United States

Closed for recruitment

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249 · Phase 2 · France

Opened for recruitment

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, China

Closed for recruitment

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449 · Phase 1/2 · Argentina, China, Czechia, United Kingdom, Japan, Mexico

Status changed: Recruiting → Not yet recruiting

Boosting Osimertinib Blood Brain Barrier Penetration

NCT07485452 · Phase 2 · Netherlands

Status changed: Recruiting → Not yet recruiting

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

NCT07158489 · Phase 2 · Switzerland, Ireland

Closed for recruitment

PET-imaging of Two Vartumabs in Patients With Solid Tumors

NCT06645808 · Early Phase 1 · Netherlands

Closed for recruitment

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

NCT03467360 · Phase 1 · France, Monaco

Opened for recruitment

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom

Closed for recruitment

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

NCT05344209 · Phase 2 · Norway

Closed for recruitment

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070 · Phase 1/2 · Canada, Spain, Hungary, Israel, Italy, South Korea

Closed for recruitment

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

NCT06457789 · Phase 2/3 · Netherlands

Closed for recruitment

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

NCT05701176 · Phase 1/2 · Netherlands

Closed for recruitment

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009 · Phase 1 · Australia, China, Denmark, Spain, Poland

Opened for recruitment

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

NCT05856695 · Phase 2 · France, Luxembourg

Closed for recruitment

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil

Opened for recruitment

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575 · Phase 2 · Brazil, Spain, France, Greece, Croatia, Hungary

Opened for recruitment

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591 · Phase 2 · Germany, Spain, Georgia, South Korea, Poland, Taiwan

Opened for recruitment

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836 · Phase 3 · Argentina, Austria, Brazil, Canada, Switzerland, Chile

Closed for recruitment

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States

Opened for recruitment

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Chile

Opened for recruitment

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154 · Phase 3 · Argentina, Brazil, Spain, Greece, Mexico, Peru

Opened for recruitment

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767 · Phase 2/3 · Australia, Canada, Spain, France, Georgia, Greece

Opened for recruitment

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774 · Phase 3 · Argentina, Austria, Australia, Belgium, Bulgaria, Brazil

Closed for recruitment

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094 · Phase 2 · Spain

Opened for recruitment

THIO Sequenced With Cemiplimab in Advanced NSCLC

NCT05208944 · Phase 2 · Australia, Bulgaria, Georgia, Hungary, Poland, Romania

Opened for recruitment

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073 · Phase 1 · Australia, Canada, China, Spain, France, United Kingdom

Opened for recruitment

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882 · Phase 1 · Australia, Germany, Spain, France, Israel, Japan

Opened for recruitment

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696 · Phase 1/2 · Austria, Belgium, Canada, China, Czechia, Germany

Opened for recruitment

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721 · Phase 3 · Argentina, Austria, Bulgaria, Brazil, Chile, Germany

Closed for recruitment

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804 · Phase 1 · Austria, Australia, Belgium, China, Germany, Spain

Opened for recruitment

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NCT06219317 · Phase 2 · Belgium, Spain, France, Italy, Netherlands

Opened for recruitment

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811 · Phase 2 · Canada, China, Spain, France, Italy, Japan

Opened for recruitment

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441 · Phase 2 · Australia, Chile, Germany, Spain, France, Georgia

Closed for recruitment

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

NCT05492682 · Phase 1 · Germany, Italy

Closed for recruitment

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305 · Phase 1 · Australia, Belgium, Brazil, Canada, China, Spain

Opened for recruitment

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan

Closed for recruitment

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 · Phase 3 · Australia, Brazil, Canada, China, Germany, Spain

Opened for recruitment

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282 · Phase 2 · Spain, France, Italy

Closed for recruitment

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280 · Phase 2 · Spain, Italy, United States

Status changed: Running, not recruiting → Not yet recruiting

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844 · Phase 3 · Belgium, Brazil, Canada, Germany, Spain, France

Opened for recruitment

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522 · Phase 2 · Australia, Belgium, Brazil, Canada, Switzerland, China

Closed for recruitment

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada

Opened for recruitment

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369 · Phase 3 · Armenia, Brazil, Germany, Spain, Georgia, Greece

Closed for recruitment

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907 · Phase 2 · Chile, Spain, Greece, Hungary, Israel, Italy

Closed for recruitment

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055 · Phase 2 · Australia, Spain, United Kingdom, South Korea, United States

Opened for recruitment

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883 · Phase 3 · China, Spain, Georgia, Greece, Hungary, India

Opened for recruitment

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786 · Phase 2 · Spain

Closed for recruitment

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813 · Phase 1 · China, Spain, Israel, Japan, Puerto Rico, Taiwan

Closed for recruitment

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

NCT07803848 · Phase 2 · Germany

Opened for recruitment

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

NCT07420439 · Phase 2 · France

Status changed: Recruiting → Not yet recruiting

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy

Status changed: Recruiting → Not yet recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706 · Phase 3 · Belgium, Canada, China, Germany, Spain, France

Status changed: Recruiting → Not yet recruiting

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583 · Phase 1/2 · Spain, France, United States

Status changed: Recruiting → Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808 · Phase 1 · Canada, Spain, France, Italy, United States

Status changed: Recruiting → Not yet recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727 · Phase 1 · Canada, Germany, Spain, France, Italy, Japan

Opened for recruitment

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France

Status changed: Recruiting → Not yet recruiting

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

NCT07843940 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France

Opened for recruitment

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

NCT07857616 · Phase 1 · United States

Stopped early

A Nutritional Supplement to Support People With Non-small Cell Lung Cancer

NCT04175769 · No phase · Canada

Closed for recruitment

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

NCT05429463 · Phase 3 · China

New in the registry

A Study to Screen for Lung Cancer in High-risk Individuals Who Have Never Smoked Using Low-dose Computed Tomography (LDCT).

NCT07914881 · No phase

Opened for recruitment

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

NCT07423117 · Phase 1 · South Korea

New in the registry

Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients

NCT07914972 · No phase

New in the registry

Application of Generative Artificial Intelligence in Perioperative Personalized Rehabilitation for Older Adults With Lung Cancer

NCT07915193 · No phase · China

New in the registry

Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)

NCT07916129 · No phase · China

Opened for recruitment

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

NCT07709585 · Phase 2 · China

Opened for recruitment

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

NCT07746388 · Phase 2 · United States

New in the registry

68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

NCT07914764 · No phase · China

Phase changed: No phase → Phase 2/3

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

NCT06457789 · Phase 2/3 · Netherlands

Phase changed: No phase → Phase 1/2

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

NCT05701176 · Phase 1/2 · Netherlands

Phase changed: No phase → Phase 4

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192 · Phase 4 · Germany, France, United States

Opened for recruitment

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

NCT07542704 · Phase 1 · United States

Closed for recruitment

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789 · Phase 2 · United States

Opened for recruitment

ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer

NCT07786909 · No phase · France